Clinical Trial Update: Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

View source ↗

Summary

A completed clinical trial update for Lung-MAP exploring biomarker-targeted second-line therapy in recurrent stage IV squamous cell lung cancer, with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Lung
• Squamous Cell Lung Carcinoma

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7 | Status: COMPLETED | Results posted: 2023-01-31